Marin Kollef, MD: Treating Pseudomonas Infections

(2:12)

Marin Kollef, MD: Results of the ASPECT-NP Study

(1:49)

C.difficile as an emerging ICU infection - Prof. Marin Kollef (US)

(20:35)

Current Topics in Respiratory Care 2018: Evaluating the Value RT Evidence - Marin H. Kollef

(50:20)

12-20-2024 - 27 y/o F with a history of obesity and a chronic cough presenting with hemoptysis

(30:45)

What we need to know for winning the battle against superbugs? - Marin Kollef

(3:41)

What to Consider When Calling For Cultures

(1:14)

Developing New Options for Antibiotic Resistant Gram-negative Bacteria

(47)

Why Are Pseudomonas Infections Getting Harder to Treat?

(1:8)

New Treatments on the Horizon for Pseudomonas Infections

(1:4)

Current Topics in Respiratory Care 2018 - Evaluating the Value of the RT: Where is the Evidence?

(44)

Pseudomonas Infections: Mortality \u0026 Health Care Costs

(54)

Pseudomonas aeruginosa in the Intensive Care Unit

(54)

ASPECT-NP: 3-Gram Dose of Ceftolozne/Tazobactam

(2:11)

What's the Strongest Approach for Treating Pseudomonas Infections?

(54)

Critical Decisions for Critical Patients: Management on Nosocomial Pneumonia in an Era of MDRO

(58:36)

Pseudomonas aeruginosa: An Overview of Treatment Options

(1:17)

Exploring Appropriate Treatment Protocols for Pseudomonas Infections

(6:28)

Core Challenges in Pseudomonas Treatment Protocol

(3:47)

Contagion Peer Exchange: Battling Resistant Pseudomonas Infections in the ICU

(41)